Skip to main content

Table 1 Demographic characteristics, N = 160,927 (2016: 32,442; 2017: 31,833; 2018: 32,098; 2019: 31,394; 2020: 33,160)

From: End-of-life care in Germany between 2016 and 2020 – A repeated cross-sectional analysis of statutory health insurance data

Characteristic

2016

n (%)

2017

n (%)

2018

n (%)

2019

n (%)

2020

n (%)

2016 to 2020 (p)**

Sex

Female

17,662

(54.4)

17,216

(54.1)

17,372

(54.1)

16,870

(53.7)

17,564

(53.0)

< 0.001

Male

14,780

(45.6)

14,617

(45.9)

14,726

(45.9)

14,524

(46.3)

15,596

(47.0)

Age group

18–50

781

(2.4)

582

(1.8)

588

(1.8)

571

(1.8)

628

(1.9)

< 0.001

51–60

2,006

(6.2)

1,755

(5.5)

1,784

(5.6)

1,750

(5.6)

1,817

(5.5)

61–70

3,768

(11.6)

3,466

(10.9)

3,614

(11.3)

3,597

(11.5)

3,956

(11.9)

71–80

8,467

(26.1)

7,153

(22.5)

6,965

(21.7)

6,473

(20.6)

6,567

(19.8)

81–90

12,364

(38.1)

12,653

(39.7)

12,602

(39.3)

12,682

(40.4)

13,431

(40.5)

> 90

5,056

(15.6)

6,224

(19.6)

6,545

(20.4)

6,321

(20.1)

6,761

(20.4)

Disease group*

HIV/AIDS

30

(0.1)

31

(0.1)

21

(0.1)

31

(0.1)

32

(0.1)

0.967

Malignant neoplasms

11,809

(36.4)

10,758

(33.8)

10,793

(33.6)

10,771

(34.3)

12,327

(37.2)

0.041

Heart diseases

24,546

(75.7)

23,463

(73.7)

23,387

(72.9)

23,018

(73.3)

24,704

(74.5)

< 0.001

Cerebrovascular diseases

10,216

(31.5)

8,798

(27.6)

8,843

(27.6)

8,328

(26.5)

9,517

(28.7)

< 0.001

Renal diseases

13,219

(40.7)

12,665

(39.8)

12,766

(39.8)

12,714

(40.5)

14,267

(43.0)

< 0.001

Liver diseases

5,621

(17.3)

4,749

(14.9)

4,699

(14.6)

4,939

(15.7)

6,175

(18.6)

< 0.001

Respiratory diseases

15,284

(47.1)

14,854

(46.7)

14,974

(46.7)

14,876

(47.4)

16,543

(49.9)

< 0.001

Neurodegenerative diseases

2,279

(7.0)

1,937

(6.1)

1,963

(6.1)

1,853

(5.9)

2,159

(6.5)

0.009

Dementia, Alzheimer’s, senility/frailty

17,382

(53.6)

14,825

(46.6)

15,054

(46.9)

14,539

(46.3)

18,076

(54.5)

0.017

  1. *At least one valid diagnosis in this group
  2. **Chi-squared test with a significance level of p ≤ .05